T-DXd Reduces Residual Disease in Early Breast Cancer Liam Davenport May 08, 2026

https://www.medscape.com/viewarticle/t-dxd-reduces-residual-disease-early-breast-cancer-2026a1000evn Neoadjuvant trastuzumab deruxtecan (T-DXd) combination therapy reduces the residual cancer burden in patients with high-risk HER2-positive early breast cancer over more conventional treatment, shows a preplanned analysis. https://www.medscape.com/c25/p14/esmo-breast-cancer-2026-2026a1000c6q